Introduction

The growing adoption of GLP-1 medications is creating new opportunities for digital health companies to support patients beyond pharmacological treatment. As weight management increasingly involves nutrition, lifestyle changes, medication monitoring and ongoing progress assessment, GLP-1 Digital Health Apps are becoming relevant tools within the broader treatment journey.

For pharmaceutical companies, healthcare technology providers and digital health platforms, understanding how patients use these applications is essential to developing effective engagement strategies.

SPER Market Research conducted quantitative research involving a target sample of 75 European GLP-1 users to examine digital application adoption, usage patterns, satisfaction and willingness to pay for premium features. The findings reveal that 69% of respondents use at least one digital application, with weight tracking, nutrition monitoring and symptom logging emerging as important use cases.

The findings also complement SPER's research on GLP-1 medication app usage in the United States, providing an opportunity to explore digital health engagement across two geographic markets.

GLP-1 Digital Health Apps: Adoption and Usage Patterns in Europe

Digital application adoption among European GLP-1 users reached 69% in the study, while 31% reported not using any applications. This indicates meaningful engagement within the surveyed sample, alongside an opportunity to understand barriers to adoption.

For digital health developers, potential barriers include usability challenges, limited awareness, privacy concerns and perceived lack of usefulness.

The opportunity extends beyond increasing downloads. Platforms need to demonstrate practical value throughout the patient journey, from treatment initiation to ongoing weight management and lifestyle adjustments.

How Are GLP-1 Users Utilizing Digital Health Applications?

The research identifies four major application use cases:

Weight and progress tracking was the most frequently reported use case. This reflects the importance of monitoring changes over time and maintaining visibility into weight management progress.

Nutrition tracking ranked second, indicating demand for tools that help users monitor dietary habits alongside treatment.

Meanwhile, 44% of respondents reported symptom logging. This creates an opportunity for applications to support structured documentation of treatment experiences, including potential side effects. Such tools should complement, rather than replace, clinical assessment.

Medication reminders were used by 40% of respondents, highlighting the practical role of digital tools in supporting medication routines.

For pharmaceutical companies, these findings suggest that patient engagement platforms should connect treatment-related information with lifestyle monitoring instead of operating as isolated tracking applications.

GLP-1 Patient Engagement: Understanding Satisfaction and Digital Support

The study found that 35% of respondents used digital applications daily, while 56% reported satisfaction with their current applications. Additionally, 64% felt supported by the digital tools they used.

These findings indicate that digital health applications can contribute to the patient experience, although satisfaction and engagement are not necessarily equivalent to improved clinical outcomes or medication adherence.

For GLP-1 Patient Engagement, relevant capabilities include:

• Personalized weight and progress dashboards.
• Nutrition and lifestyle tracking.
• Medication scheduling and reminders.
• Structured symptom documentation.
• Progress reports that patients can discuss with healthcare professionals.

The broader role of connected digital care is also explored in SPER's digital health research in metabolic care across the US and Europe, which examines digital tools, patient engagement and technology adoption in metabolic health.

What Improvements Do GLP-1 Users Expect From Digital Applications?

Usability and integration emerged as important improvement priorities.

According to the research, 27% of respondents wanted simpler tracking, while 29% identified better integration as an improvement area.

These findings point toward two important product development priorities.

1. Simplifying the user experience

Frequent manual data entry can create friction. Applications should minimize unnecessary inputs, simplify dashboards and make essential tracking activities easier to complete.

2. Improving integration across health domains

Users may benefit from more connected experiences that bring together weight progress, nutrition, medication schedules and symptom records. Integration with compatible health platforms and wearable devices could further reduce fragmented information.

For digital health providers, interoperability and usability should be considered core product requirements rather than optional enhancements.

Monetization Potential for GLP-1 Weight Management Apps

The research indicates that 30% of respondents were willing to pay for digital application features. This suggests a potential premium segment, although willingness to pay does not necessarily translate into actual purchasing behaviour.

Digital health providers could explore premium offerings built around:

• Advanced progress analytics.
• Personalized nutrition tracking.
• Enhanced reporting and visualization.
• Connected health data management.
• Additional lifestyle management features.

However, pricing strategies should account for differences in European healthcare systems, consumer purchasing power, data privacy expectations and the availability of existing healthcare services.

A sustainable monetization strategy should demonstrate clear additional value rather than placing essential treatment-support features behind expensive subscriptions.

Industry Insights: What This Means for Pharmaceutical and Digital Health Companies

The findings suggest that the next opportunity in GLP-1 Digital Health Apps lies in building connected patient-support experiences.

Industry developments reinforce this direction. In September 2025, Novo Nordisk and smartpatient introduced a digital obesity-care support program in Germany through the MyTherapy platform. The program combines treatment support, lifestyle coaching and personalized education, illustrating how digital platforms can extend beyond basic tracking.

Regulation is another important consideration. The European Union's European Health Data Space (EHDS) framework establishes a framework for accessing, controlling and exchanging electronic health data, with phased implementation. This makes interoperability, data protection and transparent consent increasingly important considerations for digital health developers.

Three strategic priorities emerge:

1. Patient-centric product development: Build around activities users already value, particularly weight tracking and nutrition monitoring.
2. Connected digital experiences: Reduce fragmented information by integrating relevant treatment and lifestyle data.
3. Evidence-led monetization: Develop premium features around demonstrated user needs while maintaining transparent pricing and responsible data practices.

Pharmaceutical companies can explore digital engagement initiatives that complement prescribed treatment, provide educational resources and help patients document their experiences. Digital health developers can focus on interoperability, intuitive tracking and personalized lifestyle support.

Digital applications should complement healthcare professionals' guidance. They should not independently recommend medication changes or substitute for clinical monitoring.

Conclusion

The research demonstrates that digital applications already play a meaningful role in the experiences of European GLP-1 users. With 69% adoption, weight tracking and nutrition monitoring leading usage, and 30% expressing willingness to pay, the findings reveal opportunities for digital health providers and pharmaceutical companies.

However, improving adoption alone will not be sufficient. Simpler tracking, better integration, relevant patient support and responsible data management will be essential to creating sustainable digital health experiences.

For companies operating in the European GLP-1 ecosystem, understanding patient preferences through continued market research can help guide product development, engagement strategies and digital health investment decisions.

Research note: This quantitative study included a target sample of 75 European GLP-1 users. Findings are directional and should not be interpreted as representative of the entire European GLP-1 user population. Larger studies across individual European markets are needed to validate these patterns and assess differences between patient segments.

Frequently Asked Questions

1. What are GLP-1 digital health apps?

GLP-1 digital health apps are mobile or web-based applications that help users organize treatment-related activities, track weight changes, monitor nutrition, record symptoms and manage medication reminders.

2. How many European GLP-1 users use digital health applications?

In SPER Market Research's quantitative study of 75 European respondents, 69% reported using at least one digital health application.

3. What are the most popular digital health app features among GLP-1 users?

Weight and progress tracking was the leading reported use case at 67%, followed by nutrition tracking at 60%, symptom logging at 44% and medication reminders at 40%.

4. How do digital health apps support GLP-1 patient engagement?

They can help users monitor progress, organize medication routines, document symptoms and track lifestyle activities. These functions can complement healthcare professional guidance.

5. Are GLP-1 users willing to pay for digital health applications?

In the study, 30% of respondents expressed willingness to pay for digital health applications, indicating potential demand for selected premium features.

6. What improvements do GLP-1 users expect from digital health apps?

The study identified better integration (29%) and simpler tracking (27%) as important improvement priorities.

7. What opportunities exist for pharmaceutical companies in GLP-1 digital health?

Pharmaceutical companies can explore digital patient-support programs, treatment education, lifestyle monitoring and connected digital experiences that complement prescribed therapies.